{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:29:56Z","timestamp":1791509396595,"version":"4.3.4"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-025-04173-w","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T10:01:37Z","timestamp":1768298497000},"page":"1023-1033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A fasting-mimicking diet in patients with mild-to-moderate Crohn\u2019s disease: a randomized controlled trial"],"prefix":"10.1038","volume":"32","author":[{"given":"C.","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-740X","authenticated-orcid":false,"given":"T.","family":"Fardeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6037-2883","authenticated-orcid":false,"given":"J.","family":"Gubatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4124-9908","authenticated-orcid":false,"given":"H.","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Temby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Keyashian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Streett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Limsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Anaizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8736-0257","authenticated-orcid":false,"given":"L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-5399","authenticated-orcid":false,"given":"S. P.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mehrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3335-1950","authenticated-orcid":false,"given":"D.","family":"Perelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0946-7534","authenticated-orcid":false,"given":"V. D.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Charu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8405-7503","authenticated-orcid":false,"given":"J. F.","family":"Ashouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6868-657X","authenticated-orcid":false,"given":"M. M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Habtezion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Sonnenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-1530","authenticated-orcid":false,"given":"C.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5104-6410","authenticated-orcid":false,"given":"S. R.","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"4173_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065186","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang, R., Li, Z., Liu, S. & Zhang, D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open 13, e065186 (2023).","journal-title":"BMJ Open"},{"key":"4173_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.cgh.2023.11.011","volume":"22","author":"S Elmasry","year":"2024","unstructured":"Elmasry, S. & Ha, C. Evidence-based approach to the management of mild Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. 22, 480\u2013483 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"4173_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1053\/j.gastro.2016.10.019","volume":"152","author":"JD Lewis","year":"2017","unstructured":"Lewis, J. D. & Abreu, M. T. Diet as a trigger or therapy for inflammatory bowel diseases. Gastroenterology 152, 398\u2013414 (2017).","journal-title":"Gastroenterology"},{"key":"4173_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/nu15030579","volume":"15","author":"J Gubatan","year":"2023","unstructured":"Gubatan, J. et al. Dietary exposures and interventions in inflammatory bowel disease: current evidence and emerging concepts. Nutrients 15, 579 (2023).","journal-title":"Nutrients"},{"key":"4173_CR5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1053\/j.gastro.2021.05.047","volume":"161","author":"JD Lewis","year":"2021","unstructured":"Lewis, J. D. et al. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn\u2019s disease. Gastroenterology 161, 837\u2013852 (2021).","journal-title":"Gastroenterology"},{"key":"4173_CR6","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jama.2014.10397","volume":"312","author":"BC Johnston","year":"2014","unstructured":"Johnston, B. C. et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 312, 923\u2013933 (2014).","journal-title":"JAMA"},{"key":"4173_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.293.1.43","volume":"293","author":"ML Dansinger","year":"2005","unstructured":"Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P. & Schaefer, E. J. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for weight loss and heart disease risk reduction: a randomized trial. JAMA 293, 43\u201353 (2005).","journal-title":"JAMA"},{"key":"4173_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai8700","volume":"9","author":"M Wei","year":"2017","unstructured":"Wei, M. et al. Fasting-mimicking diet and markers\/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci. Transl. Med. 9, eaai8700 (2017).","journal-title":"Sci. Transl. Med."},{"key":"4173_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16138-3","volume":"11","author":"S De Groot","year":"2020","unstructured":"De Groot, S. et al. Fasting mimicking diet as an adjunct to\u2009neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat. Commun. 11, 3083 (2020).","journal-title":"Nat. Commun."},{"key":"4173_CR10","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1016\/j.celrep.2019.02.019","volume":"26","author":"P Rangan","year":"2019","unstructured":"Rangan, P. et al. Fasting-mimicking diet modulates microbiota and promotes intestinal regeneration to reduce inflammatory bowel disease pathology. Cell Rep. 26, 2704\u20132719 (2019).","journal-title":"Cell Rep."},{"key":"4173_CR11","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.cgh.2025.03.020","volume":"23","author":"OM Damas","year":"2025","unstructured":"Damas, O. M. et al. A pilot randomized control trial to assess the adjunctive effect of diet on response to advanced therapies in patients with UC. Clin. Gastroenterol. Hepatol. 23, 2579\u20132587 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"4173_CR12","doi-asserted-by":"publisher","first-page":"A:5A","DOI":"10.1155\/2005\/269076","volume":"19","author":"MS Silverberg","year":"2005","unstructured":"Silverberg, M. S. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19, A:5A\u2013A:36A (2005).","journal-title":"Can. J. Gastroenterol."},{"key":"4173_CR13","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens, G. et al. Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 399, 2015\u20132030 (2022).","journal-title":"Lancet"},{"key":"4173_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1053\/j.gastro.2023.09.029","volume":"165","author":"AN Ananthakrishnan","year":"2023","unstructured":"Ananthakrishnan, A. N. et al. AGA clinical practice guideline on the role of biomarkers for the management of Crohn\u2019s disease. Gastroenterology 165, 1367\u20131399 (2023).","journal-title":"Gastroenterology"},{"key":"4173_CR15","first-page":"1571","volume":"91","author":"EJ Irvine","year":"1996","unstructured":"Irvine, E. J., Zhou, Q. & Thompson, A. K. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn\u2019s relapse prevention trial. Am. J. Gastroenterol. 91, 1571\u20131578 (1996).","journal-title":"Am. J. Gastroenterol."},{"key":"4173_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-021-01698-9","volume":"19","author":"J Roseira","year":"2021","unstructured":"Roseira, J., Sousa, H. T., Marreiros, A., Contente, L. F. & Magro, F. Short inflammatory bowel disease questionnaire: translation and validation to the Portuguese language. Health Qual. Life Outcomes 19, 59 (2021).","journal-title":"Health Qual. Life Outcomes"},{"key":"4173_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae128","volume":"19","author":"R Panaccione","year":"2025","unstructured":"Panaccione, R. et al. Achievement of endoscopic remission after induction reduces hospitalization burden in Crohn\u2019s disease: findings from a pooled post hoc analysis of risankizumab and upadacitinib phase III trials. J. Crohns Colitis 19, jjae128 (2025).","journal-title":"J. Crohns Colitis"},{"key":"4173_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0016-5085(84)80015-3","volume":"86","author":"P Sharon","year":"1984","unstructured":"Sharon, P. & Stenson, W. F. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86, 453\u2013460 (1984).","journal-title":"Gastroenterology"},{"key":"4173_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071861","volume":"11","author":"J Kikut","year":"2022","unstructured":"Kikut, J. et al. Involvement of proinflammatory arachidonic acid (ARA) derivatives in Crohn\u2019s disease (CD) and ulcerative colitis (UC). J. Clin. Med. 11, 1861 (2022).","journal-title":"J. Clin. Med."},{"key":"4173_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247584","volume":"12","author":"M Szczuko","year":"2023","unstructured":"Szczuko, M., Komisarska, P., Kikut, J., Drozd, A. & Sochaczewska, D. Calprotectin is associated with HETE and HODE acids in inflammatory bowel diseases. J. Clin. Med. 12, 7584 (2023).","journal-title":"J. Clin. Med."},{"key":"4173_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/foods10020314","volume":"10","author":"N Faizo","year":"2021","unstructured":"Faizo, N., Narasimhulu, C. A., Forsman, A., Yooseph, S. & Parthasarathy, S. Peroxidized linoleic acid, 13-HPODE, alters gene expression profile in intestinal epithelial cells. Foods 10, 314 (2021).","journal-title":"Foods"},{"key":"4173_CR22","doi-asserted-by":"crossref","unstructured":"Henderson, W. R. Jr The role of leukotrienes in inflammation. Ann. Intern. Med. 121, 684\u2013697 (1994).","DOI":"10.7326\/0003-4819-121-9-199411010-00010"},{"key":"4173_CR23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/ibd.20403","volume":"14","author":"F Stanke-Labesque","year":"2008","unstructured":"Stanke-Labesque, F., Pofelski, J., Moreau-Gaudry, A., Bessard, G. & Bonaz, B. Urinary leukotriene E4 excretion: a biomarker of inflammatory bowel disease activity. Inflamm. Bowel Dis. 14, 769\u2013774 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"4173_CR24","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1084\/jem.20091240","volume":"206","author":"S Paruchuri","year":"2009","unstructured":"Paruchuri, S. et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J. Exp. Med. 206, 2543\u20132555 (2009).","journal-title":"J. Exp. Med."},{"key":"4173_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3109\/00365529509093234","volume":"30","author":"A Ikehata","year":"1995","unstructured":"Ikehata, A. et al. Altered leukotriene B4 metabolism in colonic mucosa with inflammatory bowel disease. Scand. J. Gastroenterol. 30, 44\u201349 (1995).","journal-title":"Scand. J. Gastroenterol."},{"key":"4173_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.devcel.2012.02.003","volume":"22","author":"PV Afonso","year":"2012","unstructured":"Afonso, P. V. et al. LTB4 is a signal relay molecule during neutrophil chemotaxis. Dev. Cell 22, 1079\u20131091 (2012).","journal-title":"Dev. Cell"},{"key":"4173_CR27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/ibd\/izy349","volume":"25","author":"J Diab","year":"2019","unstructured":"Diab, J. et al. A quantitative analysis of colonic mucosal oxylipins and endocannabinoids in treatment-naive and deep remission ulcerative colitis patients and the potential link with cytokine gene expression. Inflamm. Bowel Dis. 25, 490\u2013497 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"4173_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2023.106741","volume":"168","author":"Y Ben-Mustapha","year":"2023","unstructured":"Ben-Mustapha, Y. et al. Altered mucosal and plasma polyunsaturated fatty acids, oxylipins, and endocannabinoids profiles in Crohn\u2019s disease. Prostaglandins Other Lipid Mediat. 168, 106741 (2023).","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"4173_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100705","volume":"66","author":"A Koudelka","year":"2024","unstructured":"Koudelka, A. et al. Lipoxin A4 yields an electrophilic 15-oxo metabolite that mediates FPR2 receptor-independent anti-inflammatory signaling. J. Lipid Res. 66, 100705 (2024).","journal-title":"J. Lipid Res."},{"key":"4173_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100734","volume":"66","author":"RM McGuffee","year":"2024","unstructured":"McGuffee, R. M., Luetzen, M. A. & Ford, D. A. Resolving lipoxin A4: endogenous mediator or exogenous anti-inflammatory agent? J. Lipid Res. 66, 100734 (2024).","journal-title":"J. Lipid Res."},{"key":"4173_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-018-2136-6","volume":"18","author":"JS Finnell","year":"2018","unstructured":"Finnell, J. S., Saul, B. C., Goldhamer, A. C. & Myers, T. R. Is fasting safe? A chart review of adverse events during medically supervised, water-only fasting. BMC Complement. Altern. Med. 18, 67 (2018).","journal-title":"BMC Complement. Altern. Med."},{"key":"4173_CR32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner, D. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570\u20131583 (2021).","journal-title":"Gastroenterology"},{"key":"4173_CR33","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.3748\/wjg.v25.i19.2354","volume":"25","author":"E Sollelis","year":"2019","unstructured":"Sollelis, E. et al. Combined evaluation of biomarkers as predictor of maintained remission in Crohn\u2019s disease. World J. Gastroenterol. 25, 2354\u20132364 (2019).","journal-title":"World J. Gastroenterol."},{"key":"4173_CR34","first-page":"1386","volume":"21","author":"G Zubin","year":"2015","unstructured":"Zubin, G. & Peter, L. Predicting endoscopic Crohn\u2019s disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm. Bowel Dis. 21, 1386\u20131391 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"4173_CR35","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1681\/ASN.2015070748","volume":"27","author":"L Mark\u00f3","year":"2016","unstructured":"Mark\u00f3, L. et al. Tubular epithelial NF-\u03baB activity regulates ischemic AKI. J. Am. Soc. Nephrol. 27, 2658\u20132669 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"4173_CR36","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1172\/JCI83260","volume":"125","author":"J Traba","year":"2015","unstructured":"Traba, J. et al. Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J. Clin. Invest. 125, 4592\u20134600 (2015).","journal-title":"J. Clin. Invest."},{"key":"4173_CR37","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","volume":"142","author":"P Rutgeerts","year":"2012","unstructured":"Rutgeerts, P. et al. Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial. Gastroenterology 142, 1102\u20131111 (2012).","journal-title":"Gastroenterology"},{"key":"4173_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","volume":"68","author":"H Schmitt","year":"2019","unstructured":"Schmitt, H. et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease. Gut 68, 814\u2013828 (2019).","journal-title":"Gut"},{"key":"4173_CR39","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1136\/gutjnl-2019-318264","volume":"69","author":"PJ Koelink","year":"2020","unstructured":"Koelink, P. J. et al. Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Gut 69, 1053\u20131063 (2020).","journal-title":"Gut"},{"key":"4173_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","volume":"63","author":"P Rutgeerts","year":"2006","unstructured":"Rutgeerts, P. et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn\u2019s disease. Gastrointest. Endosc. 63, 433\u2013442 (2006).","journal-title":"Gastrointest. Endosc."},{"key":"4173_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P.-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"4173_CR42","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821\u2013832 (2010).","journal-title":"Cell"},{"key":"4173_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02566","volume":"9","author":"L Mao","year":"2018","unstructured":"Mao, L., Kitani, A., Strober, W. & Fuss, I. J. The role of NLRP3 and IL-1\u03b2 in the pathogenesis of inflammatory bowel disease. Front. Immunol. 9, 2566 (2018).","journal-title":"Front. Immunol."},{"key":"4173_CR44","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.tim.2023.02.009","volume":"31","author":"QR Ducarmon","year":"2023","unstructured":"Ducarmon, Q. R. et al. Remodelling of the intestinal ecosystem during caloric restriction and fasting. Trends Microbiol. 31, 832\u2013844 (2023).","journal-title":"Trends Microbiol."},{"key":"4173_CR45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-2125.2008.03096.x","volume":"65","author":"D Damaskos","year":"2008","unstructured":"Damaskos, D. & Kolios, G. Probiotics and prebiotics in inflammatory bowel disease: microflora \u2018on the scope\u2019. Br. J. Clin. Pharmacol. 65, 453\u2013467 (2008).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"4173_CR46","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.advnut.2023.07.006","volume":"14","author":"R Shabkhizan","year":"2023","unstructured":"Shabkhizan, R. et al. The beneficial and adverse effects of autophagic response to caloric restriction and fasting. Adv. Nutr. 14, 1211\u20131225 (2023).","journal-title":"Adv. Nutr."},{"key":"4173_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cmet.2015.05.012","volume":"22","author":"S Brandhorst","year":"2015","unstructured":"Brandhorst, S. et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance and healthspan. Cell Metab. 22, 86\u201399 (2015).","journal-title":"Cell Metab."},{"key":"4173_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02352-x","volume":"20","author":"C Huang","year":"2022","unstructured":"Huang, C. et al. Ketone body \u03b2-hydroxybutyrate ameliorates colitis by promoting M2 macrophage polarization through the STAT6-dependent signaling pathway. BMC Med. 20, 148 (2022).","journal-title":"BMC Med."},{"key":"4173_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-nutr-071816-064916","volume":"37","author":"JC Newman","year":"2017","unstructured":"Newman, J. C. & Verdin, E. \u03b2-Hydroxybutyrate. Annu. Rev. Nutr. 37, 51\u201376 (2017).","journal-title":"Annu. Rev. Nutr."},{"key":"4173_CR50","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.cmet.2017.09.020","volume":"26","author":"N Martinez-Lopez","year":"2017","unstructured":"Martinez-Lopez, N. et al. System-wide benefits of intermeal fasting by autophagy. Cell Metab. 26, 856\u2013871 (2017).","journal-title":"Cell Metab."},{"key":"4173_CR51","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/0140-6736(91)90663-A","volume":"338","author":"P Rutgeerts","year":"1991","unstructured":"Rutgeerts, P. et al. Effect of faecal stream diversion on recurrence of Crohn\u2019s disease in the neoterminal ileum. Lancet 338, 771\u2013774 (1991).","journal-title":"Lancet"},{"key":"4173_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.imlet.2023.01.003","volume":"253","author":"AA Filardy","year":"2023","unstructured":"Filardy, A. A., Ferreira, J. R. M., Rezende, R. M., Kelsall, B. L. & Oliveira, R. P. The intestinal microenvironment shapes macrophage and dendritic cell identity and function. Immunol. Lett. 253, 41\u201353 (2023).","journal-title":"Immunol. Lett."},{"key":"4173_CR53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nri3738","volume":"14","author":"AM Mowat","year":"2014","unstructured":"Mowat, A. M. & Agace, W. W. Regional specialization within the intestinal immune system. Nat. Rev. Immunol. 14, 667\u2013685 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"4173_CR54","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.cgh.2024.02.009","volume":"22","author":"N Narula","year":"2024","unstructured":"Narula, N. et al. Defining endoscopic remission in Crohn\u2019s disease: MM-SES-CD and SES-CD thresholds associated with low risk of disease progression. Clin. Gastroenterol. Hepatol. 22, 1687\u20131696 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"4173_CR55","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41430-024-01487-9","volume":"78","author":"A Marsh","year":"2024","unstructured":"Marsh, A. et al. A pilot randomized controlled trial investigating the effects of an anti-inflammatory dietary pattern on disease activity, symptoms and microbiota profile in adults with inflammatory bowel disease. Eur. J. Clin. Nutr. 78, 1072\u20131081 (2024).","journal-title":"Eur. J. Clin. Nutr."},{"key":"4173_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2019.06.023","volume":"67\u201368","author":"G Bodini","year":"2019","unstructured":"Bodini, G. et al. A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. Nutrition 67\u201368, 110542 (2019).","journal-title":"Nutrition"},{"key":"4173_CR57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.gastro.2019.09.024","volume":"158","author":"SR Cox","year":"2020","unstructured":"Cox, S. R. et al. Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. Gastroenterology 158, 176\u2013188 (2020).","journal-title":"Gastroenterology"},{"key":"4173_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/00042737-200503000-00019","volume":"17","author":"MCE Lomer","year":"2005","unstructured":"Lomer, M. C. E. et al. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn\u2019s disease. Eur. J. Gastroenterol. Hepatol. 17, 377\u2013384 (2005).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"4173_CR59","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00042737-200102000-00003","volume":"13","author":"MC Lomer","year":"2001","unstructured":"Lomer, M. C., Harvey, R. S., Evans, S. M., Thompson, R. P. & Powell, J. J. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn\u2019s disease. Eur. J. Gastroenterol. Hepatol. 13, 101\u2013106 (2001).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"4173_CR60","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/CEG.S267172","volume":"14","author":"R De Sire","year":"2021","unstructured":"De Sire, R. et al. Exclusive enteral nutrition in adult Crohn\u2019s disease: an overview of clinical practice and perceived barriers. Clin. Exp. Gastroenterol. 14, 493\u2013501 (2021).","journal-title":"Clin. Exp. Gastroenterol."},{"key":"4173_CR61","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/MPG.0000000000002847","volume":"71","author":"P Mehta","year":"2020","unstructured":"Mehta, P., Pan, Z., Furuta, G. T., Kim, D. Y. & de Zoeten, E. F. Parent perspectives on exclusive enteral nutrition for the treatment of pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 71, 744\u2013748 (2020).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"4173_CR62","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf (2017)."},{"key":"4173_CR63","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1111\/j.1572-0241.2008.02176.x","volume":"103","author":"KT Thia","year":"2008","unstructured":"Thia, K. T. et al. Defining the optimal response criteria for the Crohn\u2019s disease activity index for induction studies in patients with mildly to moderately active Crohn\u2019s disease. Am. J. Gastroenterol. 103, 3123\u20133131 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"4173_CR64","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands, B. E. et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N. Engl. J. Med. 350, 876\u2013885 (2004).","journal-title":"N. Engl. J. Med."},{"key":"4173_CR65","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/biomet\/93.3.491","volume":"93","author":"Y Benjamini","year":"2006","unstructured":"Benjamini, Y., Krieger, A. M. & Yekutieli, D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika 93, 491\u2013507 (2006).","journal-title":"Biometrika"},{"key":"4173_CR66","unstructured":"Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Psychology Press, 2009)."},{"key":"4173_CR67","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin, P. C. & Stuart, E. A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34, 3661\u20133679 (2015).","journal-title":"Stat. Med."},{"key":"4173_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10387-7","volume":"10","author":"SJS Rubin","year":"2019","unstructured":"Rubin, S. J. S. et al. Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases. Nat. Commun. 10, 2686 (2019).","journal-title":"Nat. Commun."},{"key":"4173_CR69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/978-1-0716-1266-8_27","volume":"2276","author":"AL Souza","year":"2021","unstructured":"Souza, A. L. & Patti, G. J. A protocol for untargeted metabolomic analysis: from sample preparation to data processing. Methods Mol. Biol. 2276, 357\u2013382 (2021).","journal-title":"Methods Mol. Biol."},{"key":"4173_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24031987","volume":"24","author":"T Cajka","year":"2023","unstructured":"Cajka, T. et al. Optimization of mobile phase modifiers for fast LC\u2013MS-based untargeted metabolomics and lipidomics. Int. J. Mol. Sci. 24, 1987 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"4173_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03540-y","volume":"12","author":"F-X Danlos","year":"2021","unstructured":"Danlos, F.-X. et al. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis. 12, 258 (2021).","journal-title":"Cell Death Dis."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04173-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04173-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04173-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:03:04Z","timestamp":1774018984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04173-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4173"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04173-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.D.L. has equity interest in L-Nutra and has filed patents related to the FMD. V.D.L. does not receive consulting fees from L-Nutra and has committed his shares of the company to charitable organizations. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}